Lantern Pharma establishes AI Centre of Excellence and Advanced Agentic Labs in Bengaluru

image credit- freepik

US-based Lantern Pharma Inc., a pioneer in AI-driven precision oncology and computational therapeutic development, has announced the establishment of an AI Centre of Excellence and Advanced Agentic Labs in Bengaluru.

This strategic initiative represents a critical inflection point in Lantern's evolution—transitioning from pioneering AI-enabled drug discovery in cancer to industrialising those capabilities at global scale for the broader drug development community.

As pharmaceutical companies increasingly shift from AI experimentation to enterprise-scale deployment, Lantern's Bengaluru centre will serve as the company's global scale-up center for the AI platform, providing expanded computational capacity, specialised technical talent, and follow-the-sun development cycles that enable rapid iteration and deployment of advanced AI modules and functionality. The AI centre of excellence capabilities will support both Lantern's internal pipeline and growing roster of pharmaceutical and academic collaborators globally.

The centre will expand the technical depth and throughput of Lantern's proprietary RADR^® AI platform, which currently leverages hundreds of billions of oncology-focused data points and an expanding library of sophisticated machine learning algorithms and curated disease models and knowledge objects. Critically, the initiative will accelerate development of Lantern's specialised large language model (LLM) designed to assess, optimise, and generate novel molecular candidates across diverse therapeutic applications—translating complex computational insights into precision-targeted drug development strategies. Complementing this, Lantern will expand its specialised large quantitative models (LQMs) designed to aid in assessing and optimising chemical and molecular features, which will provide generative bioinformatic and medicinal chemistry reasoning and outputs.